Related Experiment Video
Updated: Sep 30, 2026

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury
Published on: March 7, 2022
Transcription inhibitor actinomycin-D abolishes the cardioprotective effect of ischemic reconditioning
Claudia Strohm1, Miroslav Barancík, Marie von Bruehl
1Department of Experimental Cardiology, Max Planck Institute for Physiological and Clinical Research, Bad Nauheim, Germany.
Objective:
Our previous studies have suggested a role of mitogen-activated protein kinases (MAPKs) in cardioprotection in the porcine heart. To investigate, whether this could be due to modification of transcriptional events we studied the influence of actinomycin-D (act-D), a known RNA-synthesis inhibitor on (i) ischemic preconditioning, (ii) (IP)-mediated cardioprotection, (iii) transcription factors levels and MAPKs activation.
Methods:
The IP-design in our model included two cycles of 10' LAD occlusion (CO) and 10' reperfusion (RP), followed by 40' CO (index ischemia) and 60' RP. Act-D was infused intramyocardially (i.my.) or systemically (syst.) (0.05 or 0.12 mg/kg) during 15' before IP and during both RP cycles of the IP-protocol. The i.my. infusions occurred via four pairs of needles into the risk area (RA).
Results:
Systemic infusion of act-D (0.05 mg/kg) before index ischemia significantly increased the IS from 54.0+/-2.5 to 78.5+/-3.8%. IP significantly reduced the IS to 2.5+/-0.8%. Syst. of act-D completely abolished the IP-induced cardioprotection. At a dose of 0.12 mg/kg the IS was 88.6+/-1.7% of the risk area; at 0.05 mg/kg IS was 65.6+/-1.5%. Local infusion of act-D reduced the IP-induced cardioprotection in a concentration dependent manner. Syst. or i.my. infusion of DMSO in KHB did not influence the IP-induced cardioprotection. Western blot analysis with phospho-specific antibodies showed a significant increase in phosphorylation of cytosolic ERK1/2 and SAPK/JNKs at the end of IP procedure and act-D treatment inhibited IP-induced activation of these MAPKs. By Western blot analysis using phospho-specific antibodies against c-Jun, ATF-2, Elk-1 and c-Myc we found increased phosphorylation of all these transcription factors in the myocardial risk area at the end of IP protocol and both local and systemic infusion of act-D significantly (P<0.05) inhibited this increased phosphorylation. Unlike UO, act-D had no influence on the Akt-pathway but inhibited the increased expression of S100 protein induced by IP.
Conclusions:
We demonstrate in vivo that act-D, completely cancelled the IP-induced cardioprotection. The influence of act-D on cardioprotection, transcription factors, and activities of ERKs and JNKs indicates a possible transcriptional role of these MAPKs signal transduction pathways during ischemia and in IP.
Insights
Actinomycin-D (act-D) abolished ischemic preconditioning (IP)-mediated cardioprotection in pigs by inhibiting transcription factors and mitogen-activated protein kinases (MAPKs). This suggests MAPKs play a transcriptional role in cardioprotection during ischemia.
Area of Science:
- Cardiovascular Physiology
- Molecular Cardiology
- Ischemic Heart Disease
Background:
- Mitogen-activated protein kinases (MAPKs) are implicated in cardioprotection.
- The role of transcriptional events in ischemic preconditioning (IP) is not fully understood.
Purpose of the Study:
- To investigate the influence of actinomycin-D (act-D), an RNA synthesis inhibitor, on IP-mediated cardioprotection.
- To determine the effect of act-D on transcription factor levels and MAPK activation in the porcine heart.
Main Methods:
- Porcine hearts subjected to IP protocol (ischemia/reperfusion).
- Act-D administered systemically or intramyocardially before or during IP.
- Infarct size (IS) assessed.
- Western blot analysis for phosphorylated MAPKs (ERK1/2, SAPK/JNKs) and transcription factors (c-Jun, ATF-2, Elk-1, c-Myc).
Main Results:
- Systemic act-D abolished IP-induced cardioprotection and significantly increased infarct size.
- Local act-D reduced IP-mediated cardioprotection in a dose-dependent manner.
- Act-D inhibited IP-induced phosphorylation of ERK1/2, SAPK/JNKs, and transcription factors, but not the Akt pathway.
- Act-D inhibited IP-induced S100 protein expression.
Conclusions:
- Act-D completely abrogated IP-induced cardioprotection in vivo.
- MAPK signaling pathways (ERK, JNK) appear to exert their cardioprotective effects through transcriptional mechanisms during ischemia and IP.
